4-[2-(3,4,5-Trimethoxyphenyl)ethenyl]phenol | 116519-00-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 4-[2-(3,4,5-Trimethoxyphenyl)ethenyl]phenol
• CAS: 116519-00-7
• 化学式: C₁₇H₁₈O₄
• 分子量: 286.32
• InChiKey: PGNACKMMQGBVTN-UHFFFAOYSA-N

物化性质

• 熔点：
  191 °C(Solv: acetic acid, 80% (64-19-7))
• 沸点：
  440.2±40.0 °C(Predicted)
• 密度：
  1.177±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  47.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P321,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

文献信息

• Functionalized stilbene derivatives as improved vascular targeting agents
  申请人：——

  公开号：US20030149003A1

  公开（公告）日：2003-08-07

  Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.

  本发明揭示了一种新型的苯乙烯类化合物及其前药形式，其作为强效的血管靶向剂，可用于治疗实体肿瘤癌和其他与不需要的新生血管化有关的疾病。这些新型的苯乙烯类化合物是微管结合的苯乙烯类类似物，其结构与康布雷他斯汀A-1和康布雷他斯汀A-4有关。前药形式作为强效的血管靶向剂（VTAs），可用于治疗实体肿瘤癌和与视网膜新生血管化有关的疾病。
• Formulation and process for modulating wound healing
  申请人：BioMendics, LLC

  公开号：US10426742B2

  公开（公告）日：2019-10-01

  Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): wherein: L represents a linker selected from —C≡C—, (a tolan), —CH═CH— (a stilbene, preferably trans); or —CRa═CRb— a stilbene derivative; where Ra and Rb are independently H or phenyl optionally substituted with —(R3)p or —(R4)q; R1 to R4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3′, 4, 4′, and/or 5, 5′; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ≥1. Each R1 to R2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.

  本发明公开了通过调节自噬促进伤口愈合的方法和化合物。用于调节自噬的制剂包括选自具有一般结构 (I) 的化合物的第一调节化合物 (FAM)： 其中L 代表选自-C≡C-（甲苯）、-CH═CH-（二苯乙烯，最好是反式）或-CRa═CRb-二苯乙烯衍生物的连接体；其中 Ra 和 Rb 独立地是 H 或任选被-(R3)p 或-(R4)q 取代的苯基； R1至R4是独立的取代基，位于苯基环的任何可用位置，优选位于3，3′、4，4′和/或5，5′；m、n、p和q分别独立地为0、1、2或3，代表环的取代基数目，但m或n中至少有一个必须≥1。每个 R1 至 R2 独立地选自本文所述的取代基，包括但不限于羟基、烷氧基、卤代、卤代甲基和苷。制剂还可包括本文所述的辅助自噬调节化合物（AAM）。制剂可包括由化合物本身或以其它方式形成的水凝胶，并可包括盐和/或复合物。
• STILBENE DERIVATIVES AS ANTICANCER AGENTS
  申请人：Research Corporation Technologies, Inc.

  公开号：EP0641301A1

  公开（公告）日：1995-03-08
• FUNCTIONALIZED STILBENE DERIVATIVES AS IMPROVED VASCULAR TARGETING AGENTS
  申请人：Oxigene, Inc.

  公开号：EP1438281A2

  公开（公告）日：2004-07-21
• EP1438281A4
  申请人：——

  公开号：EP1438281A4

  公开（公告）日：2006-04-26